Literature DB >> 22715169

Herpes zoster-related deaths in the United States: validity of death certificates and mortality rates, 1979-2007.

Abdirahman Mahamud1, Mona Marin, Steven P Nickell, Trevor Shoemaker, John X Zhang, Stephanie R Bialek.   

Abstract

BACKGROUND: Herpes zoster (HZ) vaccine was recommended in the United States to reduce HZ-associated morbidity. Vaccination may reduce HZ-associated mortality, but no strategy exists to monitor mortality trends.
METHODS: We validated HZ coding on death certificates from California, using hospital records as the gold standard, and applied the results to national-level data to estimate HZ mortality.
RESULTS: In the validation phase of the study, among 40 available hospital records listing HZ as the underlying cause of death, HZ was the underlying cause for 21 (52.5%) and a contributing cause for 5 (12.5%). Among the 21 hospital records listing HZ as the underlying cause of death, the median age of decedents was 84 years (range, 50-99); 60% had no contraindications for HZ vaccination. Of the 37 available records listing HZ as a contributing cause of death, HZ was a contributing cause for 2 (5.4%) and the underlying cause for 6 (16.2%). Nationally, in the 7 years preceding the HZ vaccination program, the average annual number of deaths in which HZ was reported as the underlying cause of death was 149; however, based on our validation study, we estimate the true number was 78 (range, 31-118).
CONCLUSIONS: National death certificate data greatly overestimate deaths in which HZ is the underlying or contributing cause of death. The HZ vaccination program could prevent some HZ-related deaths, but the impact will be difficult to assess using national mortality data.

Entities:  

Mesh:

Year:  2012        PMID: 22715169     DOI: 10.1093/cid/cis575

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Death Certification: Errors and Interventions.

Authors:  Leah M Schuppener; Kelly Olson; Erin G Brooks
Journal:  Clin Med Res       Date:  2019-10-09

Review 2.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

Review 3.  Herpes zoster-associated mortality in Europe: a systematic review.

Authors:  Hélène Bricout; Margaret Haugh; Olugbenga Olatunde; Ruth Gil Prieto
Journal:  BMC Public Health       Date:  2015-05-05       Impact factor: 3.295

4.  Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States.

Authors:  Jose A Suaya; Shih-Yin Chen; Qian Li; Stuart J Burstin; Myron J Levin
Journal:  Open Forum Infect Dis       Date:  2014-08-02       Impact factor: 3.835

5.  Burden of vaccine-preventable disease in adult Medicaid and commercially insured populations: analysis of claims-based databases, 2006–2010.

Authors:  Girishanthy Krishnarajah; Charlotte Carroll; Julie Priest; Bhakti Arondekar; Stuart Burstin; Myron Levin
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Duration of Antiviral Prophylaxis and Risk of Herpes Zoster among Patients Receiving Autologous Hematopoietic Stem Cell Transplants: A Retrospective, Observational Study.

Authors:  Dongmu Zhang; Thomas Weiss; Yu Feng; Lynn Finelli
Journal:  Adv Ther       Date:  2017-05-15       Impact factor: 3.845

7.  Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.

Authors:  Emad A Yanni; Germano Ferreira; Morgane Guennec; Yassine El Hahi; Amale El Ghachi; François Haguinet; Emmanuelle Espie; Veronique Bianco
Journal:  BMJ Open       Date:  2018-06-07       Impact factor: 2.692

8.  Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.

Authors:  Pieter T de Boer; Alies van Lier; Hester de Melker; Albert J M van Wijck; Jan C Wilschut; Albert Jan van Hoek; Maarten J Postma
Journal:  BMC Med       Date:  2018-12-06       Impact factor: 8.775

Review 9.  Systematic review of incidence and complications of herpes zoster: towards a global perspective.

Authors:  Kosuke Kawai; Berhanu G Gebremeskel; Camilo J Acosta
Journal:  BMJ Open       Date:  2014-06-10       Impact factor: 2.692

10.  Vaccine against herpes zoster.

Authors:  Jacyr Pasternak
Journal:  Einstein (Sao Paulo)       Date:  2013 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.